Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:GLUE NASDAQ:HUMA NASDAQ:MGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$12.30+0.7%$13.17$8.04▼$25.88$333.59M2.26381,998 shs361,584 shsGLUEMonte Rosa Therapeutics$4.79-3.2%$4.95$3.50▼$12.40$304.47M1.42439,912 shs578,534 shsHUMAHumacyte$2.28-5.0%$2.42$1.15▼$8.72$372.29M1.94.15 million shs5.79 million shsMGNXMacroGenics$1.58+1.3%$1.49$0.99▼$5.10$98.42M1.59736,559 shs1.05 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+0.74%-17.67%-9.69%-4.13%-47.57%GLUEMonte Rosa Therapeutics-3.23%-15.52%+1.27%-3.62%+5.97%HUMAHumacyte-5.00%-9.88%-1.30%+74.05%-75.90%MGNXMacroGenics+1.28%-7.60%+14.49%-9.71%-57.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics3.0129 of 5 stars3.62.00.00.03.72.50.6GLUEMonte Rosa Therapeutics1.262 of 5 stars3.30.00.00.00.61.70.6HUMAHumacyte1.7073 of 5 stars3.51.00.00.01.80.80.6MGNXMacroGenics4.0165 of 5 stars3.34.00.04.40.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.11Buy$54.00339.02% UpsideGLUEMonte Rosa Therapeutics 2.67Moderate Buy$15.33220.11% UpsideHUMAHumacyte 3.00Buy$11.71413.78% UpsideMGNXMacroGenics 2.50Moderate Buy$5.33237.55% UpsideCurrent Analyst Ratings BreakdownLatest MGNX, ARCT, GLUE, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.006/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/28/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$32.005/20/2025MGNXMacroGenicsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.005/14/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.00 ➝ $3.005/14/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$131.27M2.54N/AN/A$8.90 per share1.38GLUEMonte Rosa Therapeutics$75.62M3.90N/AN/A$3.63 per share1.32HUMAHumacyte$1.57M225.27N/AN/A($0.41) per share-5.56MGNXMacroGenics$152.43M0.65N/AN/A$1.85 per share0.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/11/2025 (Estimated)GLUEMonte Rosa Therapeutics-$72.70M$0.0859.88N/AN/A3.86%2.65%1.65%8/14/2025 (Estimated)HUMAHumacyte-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)MGNXMacroGenics-$66.97M-$0.89N/AN/AN/A-36.23%-59.84%-23.45%8/5/2025 (Estimated)Latest MGNX, ARCT, GLUE, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GLUEMonte Rosa Therapeutics-$0.31N/AN/AN/A$7.23 millionN/A8/12/2025Q2 2025HUMAHumacyte-$0.15N/AN/AN/A$0.94 millionN/A8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11N/AN/AN/A$17.64 millionN/A8/5/2025Q2 2025MGNXMacroGenics-$0.59N/AN/AN/A$28.06 millionN/A5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/13/2025Q1 2025MGNXMacroGenics-$0.61-$0.65-$0.04-$0.65$9.59 million$13.19 million5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million5/8/2025Q1 2025GLUEMonte Rosa Therapeutics-$0.24$0.57+$0.81$0.57$13.57 million$84.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus Therapeutics$0.715.81%N/AN/A N/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus Therapeutics0.065.645.64GLUEMonte Rosa TherapeuticsN/A5.615.61HUMAHumacyte0.363.683.28MGNXMacroGenicsN/A3.283.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%GLUEMonte Rosa Therapeutics79.96%HUMAHumacyte44.71%MGNXMacroGenics96.89%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics16.60%GLUEMonte Rosa Therapeutics6.90%HUMAHumacyte5.10%MGNXMacroGenics13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.12 million22.62 millionOptionableGLUEMonte Rosa Therapeutics9061.51 million57.27 millionOptionableHUMAHumacyte150155.12 million147.21 millionOptionableMGNXMacroGenics43063.09 million54.89 millionOptionableMGNX, ARCT, GLUE, and HUMA HeadlinesRecent News About These CompaniesMacroGenics (MGNX) Projected to Post Earnings on TuesdayJuly 29, 2025 | marketbeat.comAnalysts Set MacroGenics, Inc. (NASDAQ:MGNX) PT at $5.71July 27, 2025 | americanbankingnews.comMacroGenics Enters Into Agreement With TerSera Therapeutics for the ...July 24, 2025 | businesswire.comMacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by BrokeragesJuly 24, 2025 | marketbeat.comMacroGenics (NASDAQ:MGNX) Stock Crosses Above Fifty Day Moving Average - Time to Sell?July 22, 2025 | marketbeat.comMacroGenics (NASDAQ:MGNX) Upgraded by Wall Street Zen to "Hold" RatingJuly 12, 2025 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) is largely controlled by institutional shareholders who own 71% of the companyJuly 11, 2025 | finance.yahoo.comMacroGenics (NASDAQ:MGNX) Share Price Crosses Below 200-Day Moving Average - Here's WhyJuly 8, 2025 | marketbeat.comMacroGenics, Inc. (MGNX) Latest Stock News & Headlines - Yahoo Finance CanadaJune 29, 2025 | ca.finance.yahoo.comMacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year aheadJune 16, 2025 | investing.comMacroGenics lands $70M 'infusion of cash' to advance clinical programsJune 13, 2025 | bizjournals.comMacroGenics: Working On That Road To RecoveryJune 11, 2025 | seekingalpha.comMacroGenics Shares Rise on Royalty-Purchase AgreementJune 10, 2025 | marketwatch.comMacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase AgreementJune 10, 2025 | globenewswire.comMacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025June 3, 2025 | globenewswire.comZacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion TechnologiesMay 23, 2025 | nasdaq.com4 Medical Product Stocks to Watch From a Challenging IndustryMay 21, 2025 | zacks.com6MGNX : 4 Analysts Assess Macrogenics: What You Need To KnowMay 20, 2025 | benzinga.comMacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial ResultsMay 16, 2025 | finanznachrichten.deEarnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50May 16, 2025 | finance.yahoo.comMacroGenics (MGNX) Reports Q1 Loss, Lags Revenue EstimatesMay 13, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGNX, ARCT, GLUE, and HUMA Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$12.30 +0.09 (+0.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$12.61 +0.31 (+2.52%) As of 08/1/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Monte Rosa Therapeutics NASDAQ:GLUE$4.79 -0.16 (-3.23%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.79 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Humacyte NASDAQ:HUMA$2.28 -0.12 (-5.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.26 -0.02 (-0.83%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.MacroGenics NASDAQ:MGNX$1.58 +0.02 (+1.28%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.56 -0.03 (-1.58%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
